1Velloso LA, Folli F, Sun X J, et al. Cross - talk between insulin and angiotensin signaling systems. Proc Nail Acad Sci USA, 1996, 93:12490 - 12495.
2Teteuya Shiuchi, Tai - xing Cui, Lan Wu, et al. ACEI inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension, 2002, 40: 329 - 334.
3Nawano M, Anai M, Funaki M, et al. Imadapril, an angiotensin -converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism, 1999, 48:1248 - 1255.
4Eros EG, Deddish PA, Marcic BM. Potentiating of bradykinin action by ACE inhibitiors. Trends Endocrinol Metab, 1999, 10:223 -229.
5Henriksen EJ, Jacob S, Kinnick TR, et al. ACE inhibition and glucose transport in insulin resistant muscle: role of brandykinin and nitric oxide. Am J Physiol, 1999, 277:332 -336.
6Leszek Kalinowski, Tomasz Matys, Ewa Chabielska, et al. Angiotensin Ⅱ AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension, 2002, 40:521 -527.
7Haffner SM, Lehto S, Ronnenuna T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction. N Engl J Med, 1998, 339:229 - 234.
8Patrick Henry, Fredefique Thomas, Athanase Benetos, et al. Impaired fasting glucose, blood pressure and cardiovascular disease. Hypertension, 2002, 40:458-463.
9Grees TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atheresclerosis risk in communities study. N Engl J Med, 2000, 342:905 -912.
10Honsson L, Lindholm LH, Niskonen L, et al. Effect of ongiotensin -converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet, 1999, 353:611 -616.
